Therapeutic product candidates


Uveitis is a heterogeneous group of diseases characterized by dangerous inflammation of the uvea. It is responsible for 10-15% of blindness in the US.13 Current treatments include steroids and have serious side effects, limiting their utility.

Apitope believes there is an unmet medical need in intermediate, posterior and panuveitis, which present the highest risk for vision loss.

Apitope is developing ATX-UV1 and ATX-UV3 for the treatment of uveitis. ATX-UV1 is currently in discovery stage and ATX-UV3 is a clinic ready potential product candidate. Candidate selection is expected for the first half of 2018.

13 Br J Ophthalmol. 2003 Jul; 87(7): 879–884.